← Back to Clinical Trials
Recruiting NCT05390918

Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Insomnia
Sponsor Jeff Bridge
Study Type INTERVENTIONAL
Phase N/A
Enrollment 235
Sex ALL
Min Age 11 Years
Max Age 18 Years
Start Date 2022-10-20
Completion 2027-02
Interventions
TAILOREnhanced Usual Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study will test the effectiveness of a sleep-related primary suicide prevention program entitled TAILOR (Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior), which includes specific behavior-change strategies for adolescents at risk of suicidal behavior who suffer from difficulties falling asleep, staying asleep, and/or insufficient sleep.

Eligibility Criteria

Inclusion: * Nationwide Children's Hospital patients * Between the ages of 11 years, 0 months, and 18 years, 11 months, inclusive at time of consent * Endorse both recent (past 90 days) suicidal ideation and sleep problems (past 30 days) * Resides with primary caregiver who has legal authority to consent to research participation Exclusion: * Suicide attempt in the past 3 months * Diagnosis of Bipolar Disorder or Psychosis * Having a change to an antipsychotic and/or mood stabilizer medication regimen within the last 2 months * Snoring at least 3 nights per week that can be heard a room or two away, even without a cold or flu or during allergy season * Gasping for air while sleeping, diagnosis of Obstructive Sleep Apnea, or turning blue within the past year * Body Mass Index \> 40 * Daytime symptoms of Restless Leg Syndrome * Diagnosis of Narcolepsy * Diagnosis of Seizures or Epilepsy, or prescribed anticonvulsant medication, within the past 4 years * Significant substance use in the p

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}